Faruqi & Faruqi, LLP has initiated a securities investigation into Vistagen Therapeutics Inc. (VTGN) following the company's announcement that its PALISADE-3 clinical trial failed to achieve its primary efficacy endpoint for fasedienol in treating social anxiety disorder. The trial failure triggered a significant market reaction, with the company's stock declining more than 81% on December 17, 2025, the day of the announcement.
The law firm is examining whether company disclosures prior to the trial results were materially misleading or incomplete. Shareholders who acquired VTGN shares between April 1, 2024 and December 16, 2025 are eligible to participate in the federal securities class action lawsuit. The deadline for investors to request lead plaintiff status in the litigation is March 16, 2026.
This timeline provides affected investors approximately three months to assess their position and consult with legal counsel regarding potential recovery options. The case represents one of several securities actions typically filed following significant stock declines tied to unfavorable clinical trial outcomes in the biopharmaceutical sector.